We could not find any results for:
Make sure your spelling is correct or try broadening your search.
bioAffinity Technologies Inc addresses the need for noninvasive diagnosis of early-stage cancer and diseases of the lung and targeted cancer treatment. It develops proprietary noninvasive diagnostic tests and cancer therapeutics using technology that preferentially targets cancer cells and cell popu... bioAffinity Technologies Inc addresses the need for noninvasive diagnosis of early-stage cancer and diseases of the lung and targeted cancer treatment. It develops proprietary noninvasive diagnostic tests and cancer therapeutics using technology that preferentially targets cancer cells and cell populations indicative of a diseased state. The company is involved in developing technologies that, in the future, will be able to detect and monitor diseases of the lung and other cancers and treat many cancers. Show more
Sales of CyPath® Lung tests continue to accelerate as sales team expands customer base of pulmonology practices bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company...
Sales of CyPath® Lung tests, onboarding of pathology practices ahead of forecasts bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company focused on the need for noninvasive...
Expanded, experienced sales team more than doubles number of physician practices ordering CyPath® Lung test year-to-date More than 547% annualized growth rate for CyPath® Lung orders in first...
bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW) shares recent Company news. CyPath® Lung Sales Ramp Up Month over Month Sales of CyPath® Lung, our noninvasive diagnostic test for the early...
Collaboration with the US Department of Defense’s largest military health organization underway bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company focused on the need...
bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company focused on the need for noninvasive, accurate tests for the detection of early-stage cancer and lung disease, today...
bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company focused on commercializing noninvasive tests for the detection of early-stage cancer and lung disease, today reported...
Wallachbeth Capital Announces Closing of bioAffinity Technologies $2.5 Million Registered Direct Offering and Concurrent Private Placement PR Newswire JERSEY CITY, N.J., March 8, 2024 JERSEY...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0.16 | 6.2015503876 | 2.58 | 2.75 | 2.28 | 75815 | 2.44400189 | CS |
4 | 0.78 | 39.7959183673 | 1.96 | 2.75 | 1.9 | 97128 | 2.42333368 | CS |
12 | 0.18 | 7.03125 | 2.56 | 2.75 | 1.76 | 91236 | 2.27578135 | CS |
26 | 1.15 | 72.3270440252 | 1.59 | 3.62 | 1.39 | 159086 | 2.31859888 | CS |
52 | 1.04 | 61.1764705882 | 1.7 | 3.62 | 0.9548 | 84952 | 2.26254088 | CS |
156 | -5.66 | -67.380952381 | 8.4 | 15.55 | 0.9548 | 559859 | 3.83081015 | CS |
260 | -5.66 | -67.380952381 | 8.4 | 15.55 | 0.9548 | 559859 | 3.83081015 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions